EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Open-label multicenter study
Colorectal Cancer Metastatic
DRUG: EO4010
Safety and tolerability of EO4010 in combination with nivolumab and/or bevacizumab, Incidences of AEs, treatment-emergent AEs (TEAEs), Serious Adverse Events (SAEs), deaths, and laboratory abnormalities using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0., 12months
Percentage of patients with shown immunogenicity, Immunogenicity will be assessed by Interferon-Î³ ELISpot, 12 months|Overall response rate, Defined as the percentage of patients who have a partial or complete response following Response Evaluation Criteria in Solid Tumors criteria, 12 months|Disease control rate, Defined as the percentage of patients who have achieved complete response, partial response or stable disease following Response Evaluation Criteria in Solid Tumors criteria, 12 months|Time to response, Defined as the time interval from first study treatment administration to partial or complete response following Response Evaluation Criteria in Solid Tumors criteria, 12 months|Duration of response, Defined as the time interval from first study treatment administration to disease progression or death in patients who achieve complete or partial response following Response Evaluation Criteria in Solid Tumors criteria, 12 months|Progression free survival, Defined as the time interval from the date of first study treatment administration to the date of progression following Response Evaluation Criteria in Solid Tumors criteria, 4months|Overall survival to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up, Defined as the time interval from the date of first study treatment administration to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up, 12 months
This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab and/or bevacizumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer